Detalhe da pesquisa
1.
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Oncologist
; 26(5): 433-438, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33687763
2.
US Food and Drug Administration regulatory updates in neuro-oncology.
J Neurooncol
; 153(3): 375-381, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34156585
3.
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Oncologist
; 22(11): 1392-1399, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835513
4.
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Clin Cancer Res
; 28(11): 2221-2228, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35101885
5.
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.
Clin Cancer Res
; 27(20): 5452-5456, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045295
6.
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
Clin Cancer Res
; 10(1 Pt 1): 16-8, 2004 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14734446
7.
Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Clin Cancer Res
; 21(20): 4545-51, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26473190